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MaAs a sequel to last week’s paper on the fundamentals of clinical trial design, this paper tackles related controversial issues:
noninferiority trials, the value of factorial designs, the importance and challenges of strategy trials, Data Monitoring
Committees (including when to stop a trial early), and the role of adaptive designs. All topics are illustrated by relevant
examples from cardiology trials. (J Am Coll Cardiol 2015;66:2886–98) © 2015 by the American College of Cardiology
Foundation.R andomized controlled trials are the corner-stone of clinical guidelines informing besttherapeutic practices; however, their design
and interpretation may be complex and nuanced.
This review explores challenging issues that may
arise and builds on the fundamentals of trial design
covered in last week’s paper.
Speciﬁcally, we offer guidance on how to design
and interpret noninferiority trials where the goal is to
demonstrate that the efﬁcacy of a new treatment is as
good as that achieved with a standard treatment.
Factorial trials, where 2 (or more) therapeutic
issues are simultaneously evaluated in the same
study, present an interesting opportunity that should
be considered more often in cardiology research.
Trials that compare substantially different alter-
native treatment strategies can be of great value in
enhancing good patient management, and we present
guidance on the topic to stimulate greater interest in
overcoming the difﬁculties in undertaking such
pragmatic studies.
All major cardiology trials have both ethical and
practicalneeds fordatamonitoringof theaccumulating
evidence over time. We provide insights into how Data
Monitoring Committees (DMCs) should function,
offering statistical guidelines and practical decision-
making considerations as to when to stop a trial early.m the *Department of Medical Statistics, London School of Hygiene and T
olumbia University Medical Center, New York-Presbyterian Hospital, and
w York. The authors have reported that they have no relationships relev
nuscript received September 24, 2015; revised manuscript received OctobFinally, there is a growing interest in adaptive
designs, but few instances of their implementation in
cardiology trials. We focus on adaptive sample size
re-estimation and enrichment strategies, with guid-
ance on when and how they may be used.
All of these issues are illustrated by experiences
from actual cardiology trials, demonstrating the real-
world implications of trial design decisions.
NONINFERIORITY TRIALS
Increasingly, major trials are conducted to see if the
efﬁcacy of a new treatment is as good as a standard
treatment (1–3). The new treatment usually has some
other advantage (e.g., fewer side effects, ease of
administration, lower cost), making it worthwhile to
demonstrate noninferiority in respect to efﬁcacy.
The standard approach to designing a non-
inferiority trial is to pre-deﬁne a noninferiority
margin, commonly called delta, for the primary
endpoint. This is the smallest treatment difference,
which, if true, would mean that the new treatment is
declared inferior. This is on the basis of the belief that
any difference smaller than this would constitute
clinically accepted grounds of “therapeutic inter-
changeability” (4). The trial’s conclusions then
depend on where the 95% conﬁdence interval (CI) forropical Medicine, London, United Kingdom; and the
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AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome
CI = conﬁdence interval
CV = cardiovascular
DMC = Data Monitoring
Committee
MI = myocardial infarction
OMT = optimal medical
therapy
PCI = percutaneous coronary
intervention
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2887the treatment difference ends up in relation to this
margin. If the upper bound of the 2-sided 95% CI is
less than delta, one can claim evidence that the new
treatment is noninferior.
For instance, the ACUITY (Acute Catheterization
and Urgent Intervention Triage Strategy) trial
compared bivalirudin with the standard treatment of
heparin plus a glycoprotein IIb/IIIa inhibitor in pa-
tients with acute coronary syndrome (ACS) for 30-day
composite ischemia (death, myocardial infarction
[MI], or revascularization) (5). The noninferiority
margin was set at a relative risk of 1.25. The trial’s
ﬁndings revealed composite ischemia rates of 7.8%
and 7.3% in the bivalirudin and control groups,
respectively, with relative risk: 1.08; 95% CI: 0.93 to
1.24. Because the upper bound of the CI of 1.24 was less
than the pre-declared delta of 1.25, one can conclude
that there is evidence of noninferiority. The reason this
matters is that bivalirudin also had a markedly lower
risk of major bleeding, an important consideration
when choosing between antithrombin therapies.
A common misunderstanding is that lack of a sta-
tistically signiﬁcant difference between 2 therapies
implies that they are equivalent. For instance, the
INSIGHT (Intervention as a Goal in Hypertension
Treatment) trial compared nifedipine with co-
amilozide in hypertension. The authors concluded
that the treatments were “equally effective in pre-
venting cardiovascular complications,” on the basis
of a p value of 0.35 for the primary composite
endpoint of cardiovascular (CV) death, MI, heart
failure, or stroke (6). But, the observed relative risk of
1.10 had a 95% CI of 0.91 to 1.34. This includes up to a
34% excess risk on nifedipine, making it unwise to
conclude that nifedipine is as good as (i.e., non-
inferior to) co-amilozide.
Figure 1 shows a conceptual plot of how to interpret
the results of noninferiority trials. Scenario C (non-
inferior) indicates what happened in the ACUITY trial.
If we suppose that the INSIGHT trial had the same
delta, 1.25, then it would have fallen under scenario F
(inconclusive). Had more patients been enrolled, the
95% CI would have narrowed, and noninferiority
might then have been declared.
Sometimes, the treatment effect (and its delta) is
expressed as a difference in percentages, rather than
as a relative risk or hazard ratio (the argument being
that absolute differences are more clinically relevant
than relative risks). For instance, the OPTIMIZE
(OptimizedDuration of Clopidogrel Therapy Following
Treatment With the Zotarolimus-Eluting Stent
in Real-World Clinical Practice) trial compared a
3-month versus a 12-month duration of dual anti-
platelet therapy after implantation of a zotarolimus-eluting stent (7). For the composite primary
endpoint of net adverse clinical events (death,
MI, stroke, or major bleed) at 1 year, a 2.7%
difference was set as the noninferiority
margin. The observed difference was þ0.2%,
with a 95% CI of 1.5% to þ1.9%. Because this
excludes the margin of þ2.7%, noninferiority
of the 3-month duration of treatment was
claimed.
This example raises a few issues. When the
noninferiority margin is a difference in per-
centages, it becomes easier (perhaps too
easy) to achieve noninferiority if the overall
event rate is lower than expected. The
OPTIMIZE trial had an anticipated 9% event rate in
the control arm, but the observed event rate was 6%.
This made the 2.7% margin equivalent to a relative
risk margin of 1.45, which is undesirably large.
Conversely, if the overall event rate is greater than
expected, it may become unreasonably difﬁcult to
achieve noninferiority. The opposite considerations
of anticipated versus observed event rates apply if a
relative risk is chosen for the margin.
Also, the endpoint chosen in the OPTIMIZE trial
was not of optimal relevance. The true issue in
considering a shorter period of dual antiplatelet
treatment concerns the balance between the
increased risks of stent thrombosis and MI against the
reduced risk of major bleeding. To force these diverse
endpoints into a single composite would bias results
toward the null. A preferable approach is to pre-
specify and study separately-powered efﬁcacy and
safety endpoints, typically 1 for superiority and 1 for
noninferiority. However, a very large sample size may
be required to adequately power both the efﬁcacy and
safety endpoints.
A composite net adverse clinical events endpoint,
consisting of combined safety and efﬁcacy endpoints,
has been used in some trials, reﬂecting the recognition
that both types of endpoints (e.g., major bleeding and
stent thrombosis) are deleterious and strongly associ-
ated with subsequent mortality. However, interpreta-
tion of such a combined safety and efﬁcacy endpoint
may be challenging, especially if the different com-
ponents do not have similar effects on patients’
well-being or survival. Moreover, because safety and
efﬁcacy endpoints often move in different directions
(e.g., in response to more potent antithrombotic ther-
apies), their combination in a composite endpoint may
mask differences between therapies, making careful
examination of each component measure essential.
A key question is the choice of noninferiority
margin, which has implications for the required trial
size. Power calculations for noninferiority trials (not
FIGURE 1 Possible Outcomes in a Noninferiority Trial (Observed Difference and 95%CI)
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Conceptual ﬁgure for interpreting noninferiority trials on the basis of the estimated
absolute difference, 95% conﬁdence interval (CI), and a noninferiority margin of delta. The
vertical line at 0 represents no treatment difference. CIs to the left of the delta line
indicate noninferiority of the new treatment. Note that delta can sometimes be speciﬁed
on a relative risk scale.
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2888presented here) indicate that trial size is inversely
proportional to the square of the margin delta. For
instance, had ACUITY chosen a 10% increase, rather
than a 25% increase (i.e., relative risk 1.1, rather than
1.25), more than 6 as many patients would have
been required for the same power (i.e., >50,000 in
total). Thus, the choice of margin requires a realistic
balancing of scientiﬁc goals with an achievable sam-
ple size.
The choice of margin is sometimes related to prior
knowledge of the efﬁcacy of the active control
compared with placebo. A sensible goal is that the
new treatment should preserve at least 50% of the
effect demonstrated in prior trials of the control
treatment against placebo (the so-called “putative
placebo” approach). For instance, in the CONVINCE
(Controlled Onset Verapamil Investigation of Cardio-
vascular End Points) trial of verapamil versus stan-
dard antihypertensive treatment with a diuretic agent
or beta-blocker, the noninferiority margin for the
composite of stroke, MI, or CV death was set at a
hazard ratio of 1.16 (8). This was because of the need
for evidence that verapamil was at least one-half as
effective as the standard treatment, relative to
placebo. Regulatory agencies accept this method to
establish a noninferiority margin and provide guid-
ance for its determination (1).In addition to the assumed event rates, margin,
and desired power, the sample size of a noninferiority
trial depends on whether the delta will be tested
against the upper bound of a 1- or 2-sided 95% CI (the
latter being equivalent to a 1-sided 97.5% conﬁdence
limit). The latter conservative approach is the stan-
dard for regulatory approval of new pharmaceuticals
(and many devices). However, some devices, such as
the FilterWire EX system (Boston Scientiﬁc, Marl-
borough, Massachusetts) to prevent distal emboliza-
tion during percutaneous coronary intervention (PCI)
of diseased saphenous vein grafts, which was exam-
ined in the FIRE (FilterWire EX Randomized Evalua-
tion) trial (9), have been approved on the basis of a
noninferiority design with a 1-sided alpha of 5%.
Utilizing a 1-sided alpha of 5%, rather than 2.5%,
reduces the sample size by approximately 20%,
although this is generally frowned upon. Accepting
greater alpha error may be acceptable, however,
when the experimental device provides additional
beneﬁts not evident in the primary endpoint.
A noninferiority design may also be applied to
exclude a safety concern in a treatment with known
efﬁcacy. Such safety trials can include comparison of
the experimental agent to an active comparator. (e.g.,
as in the ENTRACTE [A Clinical Outcomes Study to
Evaluate the Effects of IL-6 Receptor Blockade With
Tocilizumab in Comparison With Etanercept on the
Rate of Cardiovascular Events in Patients With Mod-
erate to Severe Rheumatoid Arthritis] trial performed
to exclude excess CV risk for tocilizumab compared
with etanercept in patients with rheumatoid arthritis)
(10). But, in type 2 diabetes, U.S. Food and Drug
Administration guidance requires assessment of the
CV risk of any new drug relative to placebo (11). Many
such placebo-controlled trials in high-risk patients
who are already on appropriate antiglycemic therapy
are either currently in progress or recently
completed. The primary safety endpoint is typically
the composite of CV death, MI, and stroke, and the
noninferiority margin is set at a hazard ratio of 1.3.
This requires a trial of many thousands of patients,
because approximately 700 primary events are
needed to provide convincing evidence of non-
inferiority. For a new, effective antidiabetic drug, the
U.S. Food and Drug Administration also requires
preliminary evidence of CV safety for initial approval,
using a hazard ratio noninferiority margin of 1.8. The
larger safety trial to conﬁrm noninferiority on the
basis of the tougher margin of 1.3 then ensues.
It is sometimes argued that noninferiority trials
should emphasize a per-protocol (or as-treated)
analysis, rather than analysis by intention-to-treat,
thereby excluding any follow-up after a patient
TABLE 1 Displaying the Results of a Factorial Design:
CURRENT OASIS 7
First Main
Effect
Double-Dose
Clopidogrel
(n ¼ 12,520)
Standard-Dose
Clopidogrel
(n ¼ 12,566) HR (95% CI) p Value
Primary event
rates
4.17 4.43 0.94 (0.83–1.06) 0.30
Second Main
Effect
Higher-Dose
Aspirin
(n ¼ 12,507)
Lower-Dose
Aspirin
(n ¼ 12,579) HR (95% CI) p Value
Primary event
rates
4.24 4.36 0.97 (0.86–1.09) 0.61
Potential
Interaction
Primary Events by Both
Treatments Simultaneously
p Value
Double-Dose
Clopidogrel
Standard-Dose
Clopidogrel
Higher-dose
aspirin
3.8 4.6
Lower-dose
aspirin
4.5 4.2
Interaction test 0.04
Values are % unless otherwise indicated.
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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short period following withdrawal to capture rebound
events). The logic is that including off-treatment
follow-up (possibly with crossovers) may dilute any
real treatment differences, thereby artiﬁcially
enhancing any claim of noninferiority. However,
per-protocol and as-treated analyses introduce other
biases. We suggest that both types of analyses be
presented in noninferiority trials, hopefully demon-
strating a consistency of ﬁndings.
When undertaking a noninferiority trial, one can
also propose a superiority hypothesis with no statis-
tical penalty. That is, once the trial results conﬁrm
noninferiority, one can go on to test for superiority
(see scenario A in Figure 1). For instance, some CV
safety trials of antidiabetic drugs have been made
larger to accommodate this superiority hypothesis.
One such trial (EMPA-REG OUTCOME [A Randomized,
Placebo-controlled Cardiovascular Outcome trial of
Empagliﬂozin]) of empagliﬂozin versus placebo
recently demonstrated some evidence of a reduction
in the primary endpoint of CV death, MI, or stroke,
with a hazard ratio of 0.86 (95% CI: 0.74 to 0.99;
p ¼ 0.04), while also showing a signiﬁcant reduction
in all-cause death with a hazard ratio of 0.68 (95% CI:
0.57 to 0.82; p < 0.001) (12).
FACTORIAL DESIGNS
Sometimes, one can pursue 2 separate treatment
comparisons within the same major trial by random-
izing each patient twice: once to treatment A versus
its control, and at the same time, to treatment B and
its control. This is known as a 2-way factorial design
(13,14). Factorial designs have numerous practical
beneﬁts, such as adding in a second randomization
within the framework of a trial funded for a different
purpose, affording the opportunity to investigate an
inexpensive treatment that would otherwise be
difﬁcult to fund and test in its own trial. For instance,
the HOPE (Heart Outcomes Prevention Evaluation)
factorial trial studied ramipril versus placebo and
then also vitamin E versus its placebo in high-risk
patients (15,16). Ramipril signiﬁcantly reduced CV
events, whereas vitamin E did not.
In planning a factorial design, one presumes that
the treatment effect in 1 randomized comparison is
not likely to depend on the other randomized treat-
ment: that is, there is no expectation of an interaction
between the 2 randomized treatments. Thus, the trial
is powered to examine the main effects of the 2 ran-
domized comparisons separately. By doing so, one
neatly gets “2 trials for the price of 1”; that is, in
principle adding in the second randomization doesnot increase the trial size. In practice, it may be wise
to somewhat inﬂate trial size when a factorial design
is contemplated because: 1) if both treatments are
effective, the overall event rate will be lower; and
2) one may wish to guard against a modest quantita-
tive interaction being present.
The CURRENT OASIS 7 (Clopidogrel and Aspirin
Optimal Dose Usage to Reduce Recurrent Events
Seventh Organization to Assess Strategies in Is-
chemic Syndromes) trial randomized 25,086 ACS pa-
tients referred for an invasive strategy to both:
1) double-dose versus standard-dose clopidogrel; and
2) higher-dose versus lower-dose aspirin (17). The
primary outcome was CV death, MI, or stroke within
30 days, and the ﬁndings are shown in Table 1. The 2
main effect analyses showed that neither the clopi-
dogrel dose nor the aspirin dose appeared to have any
effect on the primary endpoint (p ¼ 0.30 and p ¼ 0.61,
respectively). Exploring the potential interaction
between the 2 drug doses, however, revealed a
curious ﬁnding: the observed event rate was lower on
double-dose than standard-dose clopidogrel (3.8% vs.
4.6%) when given with higher-dose aspirin, but this
was reversed (4.5% vs. 4.2%) when given with lower-
dose aspirin. This apparent qualitative interaction did
reach conventional statistical signiﬁcance: interac-
tion p ¼ 0.04. The authors believed that this unex-
pected ﬁnding lacks a known biological mechanism
and may be due to the play of chance, which is a
reasonable supposition. Conversely, if a possible
biological explanation for the interaction may be
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both arms may be jeopardized, an inherent risk of
factorial designs. Factorial designs should therefore
only be contemplated when the expectation of a
real interaction between the 2 therapies is low. In
principle, one can still undertake a factorial trial
when a plausible interaction between the 2 treatment
factors is contemplated, but this would require a
major increase in trial size to be adequately powered
to detect such an interaction.
Another useful option is a partial (or nested)
factorial design, where all recruited patients get 1
random treatment allocation, but only some patients
are eligible for the second randomized treatment. For
instance, the HORIZONS-AMI (Harmonizing Out-
comes with Revascularization and Stents in Acute
Myocardial Infarction) trial randomized 3,602 ST-
segment elevation MI patients to bivalirudin versus
heparin plus a glycoprotein IIb/IIIa inhibitor (in a 1:1
ratio) (18,19). Among these patients, 3,006 met addi-
tional anatomic inclusion criteria and underwent a
second randomization to PCI with paclitaxel-eluting
versus bare-metal stents (in a 3:1 ratio).
Occasionally the factorial design can take on more
than 2 treatment factors. For instance, the ISIS-4
(Fourth International Study of Infarct Survival) ran-
domized 58,050 patients with MI to: 1) oral captopril
versus placebo; 2) oral mononitrate versus placebo;
and 3) intravenous magnesium sulfate versus open
control in a 2  2  2 factorial design (20). Finally, the
MATRIX (Minimizing Adverse Haemorrhagic Events
by Transradial Access Site and Systemic Imple-
mentation of AngioX) trial is an example of a 3-level
randomization with a nested factorial approach. In
MATRIX, 8,404 patients with ACS undergoing cardiac
catheterization were randomized to radial versus
femoral vascular access. Among this group, 7,213 pa-
tients in whom PCI was selected for treatment were
randomized again to procedural anticoagulation with
heparin versus bivalirudin. Finally, the 3,610
bivalirudin-assigned patients were randomized a
third time to either a post-procedural prolonged
bivalirudin infusion or to no infusion (21,22).
When circumstances are right, the factorial design
is a useful means of investigating 2 (or more) different
treatment innovations within 1 trial. Overall, trialists
need to give more attention to the imaginative use of
factorial designs.
TRIALS OF ALTERNATIVE
TREATMENT STRATEGIES
Trials of fundamentally different treatment strategies,
for example, surgery versus PCI or medical therapy, orinvasive versus conservative approaches in patients
with ACS, are an exciting challenge and can have a
substantial effect on guidelines and clinical practice
(23,24). Such “strategy” trials are, however, more
difﬁcult to undertake than studies comparing different
drugs or different devices to each other.
When the randomized strategies differ substan-
tially in their perception by both investigators and
patients, particular challenges arise. Investigators
(often across specialties [e.g., cardiac surgeons and
interventional cardiologists]) need to accept that the
patient may truly receive either strategy without
being disadvantaged (i.e., a state of equipoise is
indeed present). Even if solid evidence is lacking,
physicians (and patients) may express strongly held
beliefs in the superiority of one treatment compared
to another, on the basis of anecdotal experiences or
reports, nondeﬁnitive evidence (e.g., uncontrolled
observational comparisons or small randomized tri-
als), or prior positive trials using surrogate endpoints.
These preconceived beliefs can make enrollment
more difﬁcult and may result in a biased cohort being
recruited. Obtaining informed patient consent is also
less routine in strategy trials than in standard ran-
domized drug or device studies. Strategy trials also
typically require multidisciplinary cooperation,
greater resources, and a longer period for full
recruitment, and are thus more expensive. Strategy
trials often lack a single funding source from
industry, and therefore often require pure govern-
mental and/or institutional support, collaboration
between multiple companies, or a private-public
partnership. Thus, major challenges in strategy trials
include randomizing a high enough proportion of
eligible patients in a reasonable timeframe, and
raising appropriate funds.
For instance, ISCHEMIA (International Study of
Comparative Health Effectiveness With Medical and
Invasive Approaches) is a major multinational trial of
routine invasive versus conservative strategies in
patients with stable coronary disease and at least
moderate ischemia (25). A strong evidence-based case
can be made for either approach in such patients (26).
A prior survey of interested cardiologists asked if they
would enroll their eligible patients in a randomized
trial with a 50% chance of being conservatively
managed without cardiac catheterization; 80%
responded positively (27). The ISCHEMIA trial
initially planned to recruit 8,000 patients, but after
more than 2 years, only w2,000 patients have been
randomized, which may require a protocol amend-
ment to reduce the sample size. Such lower-than-
desired recruitment is a common problem with
strategy trials.
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evaluating a new therapeutic approach. For instance,
transcatheter aortic valve replacement has emerged
as an alternative to surgical aortic valve replacement
in patients at high and prohibitive operative risk
(28,29). Ongoing trials are now being performed in
patients at lower surgical risk. Key aspects here are to
decide when in the learning curve of such a new
technology one should undertake such a trial; to
deﬁne the risk proﬁle of patients that should initially
be recruited; and to create the right collaborative
atmosphere for general cardiologists, intervention-
alists, and surgeons to participate.
The results of strategy trials require careful inter-
pretation, especially when crossovers occur. For
instance, the COURAGE (Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation)
trial studied optimal medical therapy (OMT) with and
without initial PCI in 2,287 patients with stable cor-
onary disease (30). The primary endpoint, the com-
posite rate of death or nonfatal MI, showed no
signiﬁcant difference between the PCI and medical
therapy groups after a median 4.6 years of follow-up.
A naive interpretation is that PCI is no better than
medical therapy (and thus PCI should never be per-
formed), but this ignores the strategic concept of the
trial. In the COURAGE trial, 32.5% of patients assigned
to OMT went on to receive revascularization (mostly
PCI) during follow-up, primarily for progressive or
unstable symptoms. Thus, the trial really compared
“PCI (plus OMT) now” with “OMT now, with the
option of later PCI (or coronary artery bypass graft), as
needed.” The pure question “does PCI improve
prognosis?” is not directly answerable because the
investigators could not continue with medical ther-
apy alone.
An additional concern of particular relevance to
strategy trials is that given their inherently protracted
nature (slow recruitment with long follow-up), the
standard of care frequently evolves prior to their
ﬁnish. For instance, in the SYNTAX (Synergy Between
Percutaneous Coronary Intervention with Taxus and
Cardiac Surgery) trial, coronary artery bypass graft
was shown to be superior to PCI using a ﬁrst-
generation paclitaxel-eluting stent (31). However, by
the time the SYNTAX trial was completed, second-
generation drug-eluting stents had been developed,
which have been associated with reduced rates of
death, MI, and repeat revascularization compared
with paclitaxel-eluting stents (32). Studies have sug-
gested that this advance alone might have eliminated
the difference between the 2 strategies (33). Con-
ﬁrming such a hypothesis requires performance of
another time-consuming and costly randomized trial,which, in turn, risks further advances in technology
before its completion.
Despite the practical difﬁculties in undertaking
randomized trials of alternative strategies, they are of
key importance in evaluating radically different
approaches to patient care. Otherwise, we are forced
to rely on nonrandomized comparisons on the basis
of patient registries. They, too, provide a wealth of
interesting data, but always with the caveat that
substantial selection bias is typically present, result-
ing in unmeasured confounders that cannot be
accounted for in statistical analysis (34,35).
One exciting development is the growth of prag-
matic trials that are embedded within routine care
delivery (i.e., trials with patient registries, such as the
TASTE (Thrombus Aspiration in ST-Elevation
Myocardial Infarction in Scandinavia) trial of
thrombus aspiration for MI [36]). Such trials greatly
enhance patient representativeness, recruitment, and
follow-up, with associated reduced trial costs. How-
ever, they are best suited to assess endpoints reliably
tracked in administrative databases, such as all-cause
mortality.
DATA MONITORING FOR EFFICACY,
SAFETY, AND FUTILITY
Most major randomized trials require interim ana-
lyses of the accumulating outcome data by treatment
group. Such unblinded interim analyses are produced
by an independent statistician and are evaluated by
an independent DMC, comprising of several clinicians
plus a statistician, all of whom have no other
involvement in the trial and operate under strict
conﬁdentiality (37,38).
The main DMC responsibility is to protect patient
safety, that is, to identify and react to any evidence of
harm occurring to patients, especially on the new
treatment. Adverse events may relate to pre-deﬁned
safety issues (e.g., bleeding on antiplatelet drugs),
unexpected event types, or inferiority with regard to
primaryor secondary event outcomes. TheDMCshould
meet regularly so that any ethical concerns regarding
potential harm can be dealt with in a timely fashion. If
safety issues become evident, the DMC may request
more data analyses and schedule follow-up meetings
more frequently. TheDMCcan recommend to the study
leadership that the trial be stopped or altered. How-
ever, given the likelihood of chance variations in
repeated looks at accumulating data, major alterations
should only be recommended if truly convincing evi-
dence of harm is present, with a lower threshold to
modify or stop the trial for concerns relating to
increased mortality, as opposed to other endpoints.
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whether there is overwhelming evidence for superi-
ority of the new treatment, which is sufﬁciently
convincing to merit stopping the trial early. However,
trials that are stopped early tend to overestimate true
treatment effects. Thus, early trial stoppage should
only be recommended for situations in which
continuing would truly place the control group
patients at harm (e.g., increased mortality, resulting
in an ethical imperative to unblind and expedite
approval of the experimental treatment).
Sometimes there is a third futility issue for the
DMC to consider. That is, does the accumulating
evidence indicate that the new treatment lacks efﬁ-
cacy? If there is little chance of the trial achieving a
clinically-relevant positive outcome, the trial may be
stopped early for futility. Such a decision needs
careful consideration, as even if the primary endpoint
lacks efﬁcacy, secondary endpoints with real clinical
value may emerge as positive (even if only hypothe-
sis-generating).
A further DMC responsibility is to look at trial
quality issues. For instance, if problems with
noncompliance, missing visits/data, or slowness in
event adjudication are evident, the DMC should pro-
vide feedback to the study leadership to facilitate
improvements.
After every interim report and meeting, the DMC
needs to promptly communicate its recommenda-
tions to the trial’s principal investigator (e.g., the
chair of the Executive Committee) or, sometimes,
directly to the trial sponsor in writing (or sooner by
phone, if major issues of patient safety are apparent).
All DMC-related activities should be documented
in a DMC Charter (39). This should include any sta-
tistical stopping guidelines (40), recognizing that
these are not formal rules; the recommendation to
stop rests on the wise judgment of the DMC on the
basis of the totality of evidence at their disposal, both
within the trial and externally. Note that the DMC
only makes recommendations: any decisions on
stopping or modifying the trial are the responsibility
of the trial Executive Committee or sponsor. So, what
makes for sensible statistical stopping guidelines?
First, stopping for superiority of a new treatment
requires proof beyond a reasonable doubt. For
example, a p value <0.001 is often used, or even a
p value <0.0001 at a relatively early interim analysis.
Furthermore, it is wise not to look too early or too often
for superiority: 2 or 3 interim looks should sufﬁce.
For instance, the PARADIGM-HF (Prospective Com-
parison of ARNI [Angiotensin Receptor–Neprilysin In-
hibitor] with ACEI [Angiotensin-Converting–Enzyme
Inhibitor] to Determine Impact on Global Mortalityand Morbidity in Heart Failure) trial of LCZ696
versus enalapril in chronic heart failure required
a p value <0.001 for both the composite primary
endpoint (CV death or hospitalization for heart
failure) and CV death alone at its second interim
analysis, when two-thirds of primary events had
occurred (41). Both boundaries were crossed, and the
DMC duly recommended stopping.
Of note, achieving a statistical guideline does not
automatically mean the trial is stopped. For instance,
in the SHIFT (Systolic Heart Failure Treatment with
the If Inhibitor Ivabradine Trial) trial of ivabradine
versus placebo, superiority was present at the second
planned interim analysis for both the composite pri-
mary endpoint (CV death and hospitalization for
heart failure) and all-cause death: p <0.0001 and p ¼
0.0014, respectively (42). The pre-deﬁned stopping
boundary was a p value <0.001 for the primary
endpoint. However, the DMC recommended contin-
uation: there were only a few months to go to com-
plete enrollment, important subgroup issues needed
resolving, event adjudication was incomplete, and a
previous related trial (BEAUTIFUL [Morbidity-
Mortality Evaluation of the If Inhibitor Ivabradine in
Patients with Coronary Disease and Left-Ventricular
Dysfunction]) had been neutral (43). Upon trial
completion, the primary endpoint ﬁnding was
conﬁrmed, but all-cause mortality was no longer
signiﬁcant (p ¼ 0.09). Such “regression to the truth”
may often arise. That is, interim ﬁndings that cross a
stopping boundary may be “on a random high,” so
that subsequent results (if the trial continues) may
end up less impressive (44).
Second, stopping for futility has 2 types of statisti-
cal guidelines (40,45). One approach is to see if the
95% CI for the primary endpoint effect estimate
excludes a pre-declared minimum beneﬁt, and then
stop the trial early. For instance, in the PERFORM
(Prevention of Cerebrovascular and Cardiovascular
Events of Ischaemic Origin with Terutroban in Pa-
tients with a History of Ischaemic Stroke or Transient
Ischaemic attack) trial, the primary endpoint was the
composite of CV death, MI, or ischemic stroke (46). At
the 20th safety report, the hazard ratio was 1.04 (95%
CI: 0.95 to 1.14). This excluded the pre-deﬁned 7%
beneﬁt (i.e., a hazard ratio of 0.93), and so the DMC
recommended that the trial be stopped for futility.
An alternative approach uses conditional power:
that is, if the interim data indicate only a slim chance
of achieving statistical signiﬁcance upon trial
completion, then stopping early for futility may be
reasonable. This method was applied in the RED-HF
(Reduction of Events by Darbepoetin Alfa in Heart
Failure) trial of darbepoetin alfa versus placebo in
TABLE 2 Planned Stopping Boundaries for an Event-Driven,
13,000-Patient, Placebo-Controlled Trial of Patients at
High CV Risk
Interim
Analysis
Number of
Primary Events
(%)
Stopping Boundaries*
Superiority Futility
p Value HR p Value HR
1 800 (50) <0.0002 <0.768 >0.758 >0.979
2 1,200 (75) <0.0002 <0.806 >0.216 >0.931
Final 1,600 (100) <0.05 <0.906
*There are no formal stopping boundaries for safety.
CV ¼ cardiovascular; HR ¼ hazard ratio.
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2893heart failure patients with anemia (47). Futility was
considered at each interim analysis: if the conditional
power under the protocol-speciﬁed hazard ratio of
0.8 for the composite primary endpoint (death
or heart failure hospitalization) was <30%, then
the DMC could recommend the trial be stopped.
This boundary was eventually crossed, but the DMC
decided to allow the trial to continue: there were no
safety concerns and there were signiﬁcant quality of
life improvements (a secondary endpoint).
Third, stopping for safety usually requires more
frequent looks at interim data, because there is an
ethical obligation to stop promptly if a new treatment
is causing harm (48). Also, the stopping boundary
needs to be less stringent; for example, a
p value <0.01 going the wrong way for the primary
endpoint or all-cause mortality is a useful simple
guideline. For instance, in the ILLUMINATE (Inves-
tigation of Lipid Level Management to Understand its
Impact in Atherosclerotic Events) trial of torcetrapib
versus placebo in high-risk patients, the DMC
observed 82 deaths in the treatment arm versus 51
deaths with control (p ¼ 0.007), which was the prime
reason for stopping the trial for harm (49). As a
consequence, the sponsor withdrew the drug imme-
diately from any further investigation worldwide.
Similarly, the PALLAS (Permanent Atrial Fibrilla-
tion Outcome Study Using Dronedarone on Top of
Standard Therapy) trial of dronedarone versus pla-
cebo in permanent atrial ﬁbrillation was stopped early
when both coprimary endpoints of: 1) stroke, MI,
systemic embolism, or CV death; and 2) unplanned
hospitalization for a CV cause or death, demonstrated
an excess on dronedarone (both p < 0.01) (50). This
was particularly surprising, given that the earlier
ATHENA (A Placebo-Controlled, Double-Blind, Paral-
lel Arm Trial to Assess the Efﬁcacy of Dronedarone
400 mg bid for the Prevention of Cardiovascular
Hospitalization or Death from Any Cause in Patients
with Atrial Fibrillation/Atrial Flutter) trial of drone-
darone in nonpermanent/paroxysmal atrial ﬁbrilla-
tion had shown a highly signiﬁcant beneﬁt (51). This
illustrates the importance of the safety role of a DMC,
no matter how promising the prior evidence from
other sources.
Stopping early for harm may relate not to the efﬁ-
cacy endpoints, but to speciﬁc safety problems
instead. For instance, at an early interim report, the
APPRAISE 2 (Apixaban for Prevention of Acute
Ischemic Events 2) trial of apixaban versus placebo in
ACS patients showed signiﬁcant increases in major
bleeding events for those on apixaban (52). Numbers
of events were small, but given that the primary
efﬁcacy endpoint of CV death, MI, or ischemic strokehad thus far showed no beneﬁt, this safety signal was
deemed sufﬁcient to halt the trial. In such scenarios
of potential harm, it is difﬁcult to have a statistical
stopping guideline that adequately captures the
ethical concern, which needs balancing against
potential beneﬁt regarding efﬁcacy endpoints. Such
matters depend on an experienced DMC acting
wisely, being fully aware of the ethical and practical
consequences of its actions.
Let us conclude this section with potential stop-
ping guidelines for a planned placebo-controlled trial
of a new drug for patients at high CV risk. The trial is
to recruit 13,000 patients, and completion is planned
when 1,600 primary major adverse CV events have
occurred, anticipated to take >5 years duration in
total. This gives 90% power to detect a 15% risk
reduction (i.e., hazard ratio: 0.85). The trial plans to
have 2 interim analyses, after 50% and 75% of primary
events have occurred, and the proposed stopping
boundaries for superiority and for futility are shown
in Table 2.
First, the timing of these boundaries recognizes that
stopping for either superiority or futility should not be
contemplated before at least one-half of the trial’s
evidence has accumulated. The superiority guideline
(p < 0.0002) reﬂects the spirit of only stopping when
there is overwhelming evidence. It is interesting to
note that to stop early, the hazard ratios for the major
adverse CV event primary endpoint at the 2 interim
looks would need to be <0.768 and <0.806, respec-
tively, considerably more beneﬁcial than the hazard
ratio of 0.85 used in the power calculation. Given the
tough stopping boundary, the ﬁnal p value <0.05 for a
positive outcome is not compromised, and with 1,600
primary events, an observed hazard ratio <0.906
would reach statistical signiﬁcance.
The stopping guidelines for futility in Table 2 are
on the basis of conditional power calculations. With
50% of the event data in (800 primary endpoint
events), if the hazard ratio is only very slightly in a
positive direction (hazard ratio >0.979) or in the
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By adding a further 25% of events at the second
interim analysis (1,200 events), one would need a
somewhat stronger indication of treatment beneﬁt to
continue: hazard ratio >0.931 is considered sufﬁcient
to stop for futility. Note these are not intended as
absolute rules. There may be other issues (secondary
endpoints, safety concerns, subgroup ﬁndings, or
external evidence) that could sway the totality of
evidence in a positive or negative direction.
Last, note the lack of any formal stopping bound-
aries for safety. Experience dictates that it is
impractical to capture all the scenarios and nuances
of potential harms in statistical guidelines. Rather,
the trial DMC will receive frequent safety reports
every few months and will collectively make judg-
ments on the strength of evidence and the absolute
magnitude and seriousness of any safety signals.
ADAPTIVE DESIGNS
The conventional wisdom in clinical trial design is that
once the study protocol is ﬁnalized, the trial should
proceed with no further changes to its intent. Protocol
amendments are permitted under certain circum-
stances, but should be made without knowledge of
interim results by treatment groups: that is, the DMC
should have no involvement in such changes. Such
amendmentsmay be of a practical nature, for example,
clariﬁcations of patient eligibility, endpoint deﬁni-
tions, or drug dose modiﬁcations. Amendments in
response to knowledge of ongoing blinded results
for all treatments combined are also permitted. For
instance, if the incidence of the primary endpoint
pooled across randomized groups is substantially
lower than anticipated, the target sample sizemight be
increased, the eligibility criteria might be changed to
recruit higher-risk patients, the duration of follow-up
might be prolonged, or the primary endpoint might
even be altered (e.g., by expanding a composite to
include additional types of outcomes). In principle,
such adaptations are acceptable and carry no statistical
penalties, although they may prompt concerns that
someone involved had an awareness of unblinded re-
sults. In particular, changing the primary endpoint
often evokes suspicion, even if unwarranted.
An emerging and more controversial type of
adaptive design is where protocol changes are made
on the basis of the unblinded interim results (53,54).
Both European and U.S. regulators have issued guid-
ance on the use (and possible misuse) of such adap-
tations (55,56). It is key that any such potential
changes should be pre-deﬁned in an Adaptive Char-
ter, that they should not affect the trial’s overallintegrity, and that they should preserve statistical
rigor: that is, an unbiased verdict is still reached on
the treatments’ relative merits.
The most common adaptation using unblinded data
concerns sample size re-estimation (57). Other types of
proposed adaptive designs (54) include seamless
phase II/III trial designs, whereby from multiple new
treatments (e.g., different drug doses), one drops some
arms at an interim analysis on the basis of a surrogate
outcome, thereafter examining clinical outcomes (58);
enrichment designs, in which after the adaptation,
selected subgroups of patients are preferentially
enrolled in whom the event rates were observed to be
high or evidence of treatment effect appeared partic-
ularly robust (59); and “play the winner,” whereby the
randomization ratio is adjusted to put a higher pro-
portion of future patients on the treatment with better
interim results (60). All have a methodological appeal,
but introduce logistical and interpretive challenges.
Hence, we now concentrate on adaptive sample size
re-estimation. The logic is that if the observed treat-
ment difference for the primary endpoint at a pre-
planned interim analysis is somewhat smaller than
that assumed in the original power calculation, trial
size may be increased to provide adequate power to
detect such a more modest treatment effect. For this
approach to be valid, the interim results need to be in a
“promising zone,” that is: 1) the observed interim
treatment difference, although smaller than hoped for,
is still trending in the right direction and is big enough
to be of clinical relevance; and 2) the expansion in
sample size takes the conditional power from a current
50%þ to a desired 80% or higher. Then, the type I error
may be preserved without any statistical adjustments.
A sample size increase could also be considered if the
effect size is preserved, but the endpoint rates at the
interim analysis are lower than anticipated.
Figure 2 gives a conceptual outline of how adaptive
sample size re-estimation could work. Suppose an
interim analysis is performed after one-half of the
original trial’s results are known and that you are
prepared to increase the size (if necessary) up to
double that originally planned. Then, whether to
make any size increase depends on how the observed
treatment difference compares with the pre-planned
treatment difference used in the original power
calculation. If these rates are at least similar, then the
trial is “on track” and there is no need to increase trial
size. We call this the favorable zone; in Figure 2, this
extends to point B, where the observed difference is
approximately 90% of pre-planned difference A.
The promising zone refers to the scenario where the
observed difference is less than hoped for, but con-
ditional power can still be raised to the desirable 90%
FIGURE 2 Conceptual Outline of Sample Size Re-Estimation When in the Promising Zone
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Possible outcomes from an interim analysis for adaptive sample size re-estimation. The 3
scenarios are: 1) the favorable zone, when the observed treatment difference is similar to
the pre-planned treatment difference; 2) the promising zone, when the observed difference
is less than that hoped for, but where reasonable conditional power can be achieved by
increasing the sample size; and 3) the unfavorable zone, when interim results show poor
conditional power and the trial continues to its original size.
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observed difference is at least 66% of the pre-planned
difference (point C in Figure 2) for which a doubling of
size is needed.
One can then extend the promising zone into less
optimistic territory, where a doubling is still to be
done, even though the conditional power cannot
make it to the desired 90%. For instance, point D in
Figure 2 occurs when the interim difference is only
slightly more than one-half of the pre-planned dif-
ference. Doubling the trial size can raise the condi-
tional power up to more than 50%, which is not
hopeless, but a gamble as to whether the trial will end
up positive. If the interim results are worse than that,
then one is in the unfavorable zone. The trial then
continues to its original size (unless ﬁndings are very
unfavorable, in which case stopping for futility may
be considered). Note that Figure 2 is just conceptual:
precise statistical details would need to be calculated
(57) and speciﬁed in an Adaptive Charter.
Pre-planned adaptive sample size re-estimation
has been used in 2 trials of cangrelor versus
clopidogrel in PCI patients. In the CHAMPION (Can-
grelor versus Standard Therapy to Achieve OptimalCENTRAL ILLUSTRATION Key Challenges in Trial Design
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2896Management of Platelet Inhibition) PCI trial, after
70% of patients were enrolled, an interim analysis of
the 48-h primary endpoint was performed to deter-
mine whether the intended sample size (n ¼ 9,000)
needed expanding up to a maximum of 15,000 (61,62).
The Adaptive Charter also considered potential
enrichment with more diabetic, troponin-positive, or
clopidogrel-naive patients if it would enhance statis-
tical power. Unfortunately, there was no interim
evidence that cangrelor was superior to clopidogrel,
and the trial was stopped early for futility.
The more recent CHAMPION PHOENIX trial also
planned for adaptive sample size re-estimation; but,
in this instance, because the interim analysis showed
clear evidence of cangrelor’s superiority, there was no
need to expand beyond the original sample size target
of 10,900 patients (63).
These 2 examples provide a reality check to the
burgeoning enthusiasm some trialists express about
adaptive designs. If a trial is well planned, with a
realistic size and alternative hypothesis, then the
“promising zone” needing actual expansion of trial
size is a relatively narrow window of opportunity. We
favor incorporating pre-planned adaptive sample size
re-estimation into clinical trial designs, but
investigators should realize that the likelihood of
actively changing the study size or patient eligibility
composition (enrichment) is modest. Thus, organi-
zational simplicity, rather than complex statistical
algorithms, is recommended. Also, these calculations
can be nuanced, and a statistician experienced in
adaptive design methodology should be involved.
Despite these caveats, small biotechnology or
medical device companies that do not have the initial
resources to plan an appropriately large trial upfront
often consider an adaptive approach. Thus, they start
with a smaller trial with a potentially unrealistic
treatment-effect size, and then use “positive” interim
data to persuade funders to expand the trial. This
raises an important concern about adaptive designs:
the implicit leaking of interim ﬁndings beyond the
strict conﬁdentiality of the DMC. Only the adaptivedecision makers should be privy to interim results. If
the rationale for a trial’s adaptive increase in size is
known, people will infer the nature of the interim
ﬁndings. It is a matter of debate as to whether such
wider leakage compromises the trial’s integrity (e.g.,
by altering patient recruitment patterns).
CONCLUSIONS
The Central Illustration summarizes the key issues in
the diverse collection of design topics we have
tackled. In this series of 4 consecutive papers on
clinical trials (2 on analysis and reporting, 2 on
design) the aim has been to cover those statistical and
scientiﬁc issues of importance, with a focus on prac-
tical insights of relevance to cardiologists.
There is a substantial number of published papers
of a more technical nature that statisticians need to
master, but such issues tend to be secondary in
importance compared with grasping the essential
nontechnical factors we have discussed, many of
which represent the application of common sense to
trial design and statistics. There were some topics we
chose not to tackle. For example, Bayesian methods
are absent, partly because it is hard to do them justice
in a few pages, but also reﬂecting our view that they
have a limited role: there is a paucity of examples
where their use in cardiology trials achieved insights
not reachable by conventional methods.
It is our hope that this series may help clinical
trialists and sponsors to more effectively design
studies, statisticians interfacing with study leader-
ship to bring forward the most relevant issues to
jointly address, and cardiologists to critically inter-
pret and appraise published studies so as to effec-
tively translate clinical trial evidence to patient care.
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